10x Genomics, Inc. Form 8-K Summary
Reporting date: October 5, 2020. The filing reports a material acquisition agreement and related unregistered stock issuance. It does not provide a quarterly or annual financial update.
Business Context and Transaction
- 10x Genomics entered into an Agreement and Plan of Merger and Reorganization to acquire ReadCoor, Inc. through a two-step merger.
- ReadCoor will become a wholly owned subsidiary of 10x Genomics, with the transaction expected to close in October 2020, subject to customary closing conditions.
- The company also issued a press release discussing its recent acquisition of CartaNA AB, but the provided filing text does not describe that transaction’s financial terms or closing conditions.
Consideration and Capital Structure
- Total consideration for ReadCoor is $350 million, subject to customary purchase price adjustments and holdbacks.
- Consideration will consist of $100 million in cash, reduced for specified ReadCoor transaction expenses, indebtedness, and working-capital shortfalls, with the balance payable in shares of 10x Genomics Class A common stock.
- The number of shares will be based on the daily volume-weighted average price of 10x Genomics common stock over the 10 consecutive trading days ending on the third trading day before closing.
- The stock consideration is intended to be issued under exemptions from Securities Act registration. 10x Genomics agreed to file a Form S-3 registration statement after closing for resale of eligible shares.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, operating margins, debt, cash balances, liquidity measures, or acquisition-related financing details beyond the stated $100 million cash component.
Material Changes Versus Prior Period
The principal disclosed change is the proposed acquisition of ReadCoor and the related potential issuance of 10x Genomics equity. No comparable-period financial results are included, so changes in operating performance cannot be assessed from this filing.
Outlook, Risks, and Unusual Items
- Management expects the transaction to close in October 2020, but completion remains subject to customary conditions.
- Risks include failure to satisfy closing conditions, termination of the Merger Agreement, disruption to the company’s business from the acquisition announcement, general economic conditions, and risks affecting the company’s business and financial condition.
- The final cash amount and stock issuance may change because of purchase price adjustments, transaction expenses, indebtedness, working-capital shortfalls, and the stock-price calculation.
- The acquisition consideration represents a material use of cash and potential dilution, although the filing does not state the final number of shares to be issued or the expected effect on ownership.
Investor Verification Checklist
- Verify whether and when the ReadCoor transaction closed and the final cash and stock consideration paid.
- Verify the final number of Class A shares issued and the resulting dilution to existing shareholders.
- Review the Merger Agreement, including termination rights, closing conditions, indemnities, holdbacks, and purchase price adjustments.
- Review subsequent filings for the Form S-3 registration statement and acquisition accounting, including goodwill, intangible assets, and transaction expenses.
- Assess the company’s available cash, liquidity, and any financing used to fund the cash consideration.
- Review disclosures regarding the CartaNA AB acquisition and the strategic and financial impact of combining the acquisitions.